''Baxter’s heritage of innovation has had a far-reaching impact on patient care,'' adds Parkinson. ''Innovation is the lifeblood of growth in today’s competitive marketplace, and our R&D investment has risen steadily to reflect this reality.''
A webcast of Baxter’s 2012 Investor Conference can be accessed live from a link on the company’s website at www.baxter.com beginning at 9:00 a.m. CDT on October 9, 2012. A replay of Baxter’s 2012 Investor Conference and accompanying presentation materials can be accessed from a link on the company’s website at www.baxter.com beginning October 10. Please visit Baxter’s website for more information regarding this and future investor events and webcasts.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
This release includes forward-looking statements concerning Baxter’s
long-range plan, R&D pipeline, business development and other growth
strategies, and capital allocation philosophy. The statements are based
on assumptions about many important factors, including the following,
which could cause actual results to differ materially from those in the
forward-looking statements: demand for and market acceptance risks for
new and existing products; future actions of regulatory bodies and other
governmental authorities, including the FDA and foreign counterparts;
product quality or patient
safety concerns; U.S. healthcare
reform and other austerity measures; reimbursement and rebate policies
of government agencies and private payers; product development risks;
accurate identification of business development and growth
opportunities; timely submission and approval of regulatory filings;
inventory reductions or fluctuations in buying patterns; the impact of
geographic and product mix on the company's sales; the impact of
competitive products and pricing, drug reimportation and disruptive
technologies; the availability of acceptable raw materials and component
supply; fluctuations of supply and demand and the pricing of
plasma-based therapies; the ability to enforce company patents; patents
of third parties preventing or restricting the company’s manufacture,
sale or use of affected products or technology; realization of benefits
from joint product development and commercialization arrangements; the
impact of global economic conditions on Baxter and its customers,
including foreign governments; foreign currency fluctuations and other
risks identified in the company's most recent filing on Form 10-K and
other SEC filings, all of which are available on the company's website.
The company does not undertake to update its forward-looking statements.
Financial schedules are available on the company’s website.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV